Clinical studies have shown that IL-6R blockade with tocilizumab (8 mg per kg bodyweight every 4 weeks) or sarilumab (human anti-IL-6R monoclonal antibody (150–200 mg every 2 weeks)) is more effective than TNF-α blockade by the anti-TNF-α blocking antibody (adalimumab) in patients with RA. This evidence concerns the gene IL6R and rheumatoid arthritis.